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Introduction 
The abscopal effect (from the Latin ab- for “away from” and scopus 
for “target”) is the regression of tumors at a distance from the irra-
diated lesions; it was first described in 1953 [1]. In the last several 
decades, the abscopal effect has been discussed by radiation on-
cologists as an interesting but extremely rare phenomenon with 
little hope for application in real practice [2]. The abscopal effect is 
mediated by immunologic mechanisms. In the immunotherapy era, 
a new appreciation of the role played by anti-cancer immune sys-
The abscopal effect is a phenomenon in which radiation therapy results in the regression of meta-
static lesions at a distance from the irradiated lesions. Here, we have described a 37-year-old woman 
with advanced luminal B breast cancer who presented with severe pain at multiple sites. Multiple 
bone, lymph node, and lung metastases were found on computed tomography (CT). She refused to 
receive any systemic therapy, but she agreed to receive palliative radiotherapy (RT). Multi-site RT (25 
or 30 Gy in 5 fractions) was performed for pain palliation. The pain was completely relieved after RT. 
Furthermore, the pulmonary CT after 3 months of RT showed a dramatic regression of the previous 
multiple lung metastases. This is the case report demonstrating the abscopal effect in South Korea. 
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tems in orchestrating the anti-tumor effects of radiotherapy (RT) 
has caused a major spike in interest in the abscopal effect [3]. Here, 
we have reported a case of metastatic luminal B breast cancer 
showing the abscopal effect after multi-site five-fraction palliative 
RT and proposed some ways to increase the probability of occur-
rence of the abscopal effect. 
Case Report 
After approval by the Institutional Review Committee of Severance 
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Hospital (No. 4-2020-0947), the medical records of patients with 
breast cancer treated at our institution were examined. A patient 
who received intensity-modulated radiotherapy (IMRT) was identi-
fied and selected for study.  
A 37-year-old woman was diagnosed with metastatic luminal B 
breast cancer (estrogen and progesterone receptor positive and 
HER2 positive) in April 2018. Metastatic lesions were found in the 
lungs (bilateral), bone (the spine, sternum, rib, both pelvic bone, 
and proximal femurs), and lymph nodes (left axillary level I, the left 
supraclavicular fossa, and the mediastinum). Positron emission to-
mography (PET) and chest computed tomography (CT) showed 
multiple metastatic lesions (Figs. 1, 2). She refused to receive any 
systemic therapy because she was afraid of toxicity caused by che-
motherapy and hormone therapy. However, she agreed to receive 
palliative RT in order to relieve severe pain. 
The patient received five fractions of IMRT for painful metastatic 
bone lesions. The patient had severe pain in the right pelvis, sa-
crum, and thoracic spine. The initial pain score using the visual an-
alog scale (VAS) was 8. Simulation CT was performed using a cus-
tom-made immobilization device. The gross tumor volume (GTV) 
was contoured with the simulation CT fused with PET and diagnos-
tic CT. The clinical target volume (CTV) was defined as the consid-
eration of microscopic disease, and the planning target volume 
(PTV) was defined as an adequate margin for the CTV. A total dose 
of 22.5 Gy was delivered at 4.5 Gy to 100% of the PTV using IMRT 
to spare normal organs at risk, such as the heart, lung, bowel, and 
rectum. Linac-based volumetric modulated arc therapy was used 
for IMRT. After four fractions of RT of the thoracic spine and pelvic 
bone, the pain subsided (the VAS score reduced from 8 to 2), but 
there was new-onset pain in the left axilla and sternum (VAS score, 
6). Additional RT to the axilla was planned, and the prescribed dose 
was 25 Gy in 5 Gy. Because the left axillary metastatic mass was 
large, a simultaneous integrated boost technique was used. The 
fractional dose of 6 Gy was prescribed to the “core” of axillary 
mass. The dose distribution for the thoracic spine, pelvic bones, 
sternum, and axillary mass are shown in Fig. 3. The patient did not 
have any severe toxicity during RT. 
After 3 months of RT, the follow-up pulmonary CT revealed that 
a large mass involving the left anterior chest wall (irradiated lesion) 
and metastatic nodules in both lungs (unirradiated lesion) were 
markedly decreased in size (Fig. 4). Considering that RT was only 
administered to the chest wall mass, the decrease in the size of 
metastatic nodules in both lungs might be regarded as the absco-
pal effect. No other treatment was administered to either lung le-
sion. Severe pain in the thoracic spine, right pelvis, axilla, and ster-
num reduced from a VAS score of 8 to 0, from 8 to 2, from 8 to 2, 
and from 8 to 0, respectively. 
As respect to lymphocyte count, total lymphocyte count (TLC) 
before RT was 3,300/mm3. TLC was decreased to 640 during RT, and 
TLC was recovered to 1,150 at 1-month follow-up after RT. 
However, the patient did not want to receive any further treat-
ment and refused to visit the hospital after 3 months of follow-up. 
The patient died of the disease 14 months after RT. 
Discussion 
The abscopal effect has been described as a rare phenomenon in 
clinical practice. This rarity is caused by the fact that conventional 
Fig. 1. Positron emission tomography (PET) revealed multiple metastases (both lungs, bones, and left anterior chest wall mass). (A) Maximum 
intensity projection image. (B) Fusion axial image of PET and computed tomography.
BA
https://doi.org/10.3857/roj.2020.00990140
Tae Hyung Kim and Jee Suk Chang
RT alone is inadequate to subvert the existing immunosuppression 
or tolerance characteristics of the microenvironment of an estab-
lished tumor. However, the ability of RT to prime antitumor re-
sponses is likely to be key in not only inducing the abscopal effect 
but also obtaining therapeutic synergy with immunotherapies [4]. 
Considering Norman Coleman’s statement that “radiation is a 
different drug at different doses and fractionation schedules,” the 
dose and fractionation of RT might be linked to the abscopal effect. 
Vanpouille-Box et al. [4] provided a mechanistic explanation for 
the dose dependence of abscopal effects. A shorter course (≤3–5 
fractions) with increasing dose size per fraction (≥6–8 Gy) was as-
sociated with activated intrinsic type I interferon (IFN-I) activation 
via the cGAS/STING pathway and may be the optimal choice of 
regimen to test abscopal responses. Although there are various 
dose and fractionation schedules for palliative RT (such as 8/1, 
20/5, and 30/10), we believe that the shorter the course, the better 
the abscopal effect; shorter courses are also preferred for patients’ 
convenience.  
Many groups have insisted that lymphocytes might play a key 
role in the abscopal effect, and the degree of RT-induced lympho-
penia might influence the occurrence of the abscopal effect [5]. 
Short fractions lead to short periods of circulating lymphocyte de-
pletion and relatively faster recovery. The Yonsei Group found that 
a large RT target volume was associated with RT-induced lympho-
penia and poor survival [6]. Prevention of lymphopenia caused by 
RT might be needed to achieve the desired abscopal effect. Lambin 
et al. [5] proposed “lymphocyte-sparing RT” with the principle of “as 
low as reasonably achievable” in lymphocyte-rich regions in RT 
treatment planning. Recently, Sung et al. [7] developed a model for 
lymphocyte and RT, enabling physicians to predict the immunologi-
cal consequences of different RT dose/fractions. This model could 
provide an explanation for understanding the abscopal effect. 
Emerging data have shed light on the fact that lower tumor bur-
den is associated with better response to immunotherapy [8]. Ac-
cordingly, inter-metastasis tumor heterogeneity could be a chal-
lenge for the abscopal effect as well as immunotherapy [9]. We-
ichselbaum, who first proposed the concept of oligometastasis in 
1995 [10], suggested multi-site RT or RT to all sites because of the 
potential benefits of ablating non-immunogenic lesions [3]. Tumor 
microenvironment profiles are associated with response to immu-
notherapy. Recent studies have focused on immune checkpoint 
molecules, such as programmed death (PD)-1, PD-ligand 1 (PD-L1), 
and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which 




Fig. 2. The dose distribution for the thoracic spine, lumbar spine, pelvic bones, sternum, and axillary mass. The total dose for the thoracic and 
lumbar spine and pelvic bones was 22.5 Gy in 4.5 Gy and 30 Gy in 6 Gy for the sternum and axillary mass. (A) Axial image. (B) Sagittal image. 
(C) Coronal image.
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ported stereotactic body RT (SABR) outcomes based on local tumor 
response and tumor gene expression patterns, showing that SBRT 
increased the expression of innate and adaptive immune genes and 
decreased the expression of cell cycle and DNA repair genes. The 
limitation of our report is the lack of biopsy results. There was only 
an initial pathology report of a mastectomy specimen, and no post-
RT pathology report. If there were both pre-RT and post-RT pathol-
ogies, additional analysis would be possible. According to changed 
policies of IRB in 2013, it was impossible to access the patient’s 
pathological records without the patient’s consent. At the time of 
writing this case report, the patient had already died and we could 
Fig. 3. (A) Computed tomography scan images before radiotherapy. The blue arrow shows the left anterior chest wall mass and the yellow circle 
shows multiple lung metastases. (B) Positron emission tomography revealed metastasis of left anterior chest wall mass, both lungs, and bones.
not get consent because we couldn’t contact her guardians. Recently, 
we initiated our phase II study (NCT04017897) to investigate wheth-
er immunotherapy plus RT exhibits increased antitumor activity in 
patients with melanoma [12]. Because we could not analyze vari-
ous molecular profiles and tumor microenvironment due to ab-
sence of pathologic confirmation, we will check various molecular 
profiles and report changes in tumor microenvironment by obtain-
ing peripheral blood sample and tumor tissue in the prospective 
study. 
Several groups have provided preclinical and clinical evidence 
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Fig. 4. Computed tomography scan images after radiotherapy. The blue arrow shows the regression of the left anterior chest wall mass and the 
red circle indicates the regression of multiple lung metastases.
cancer cells, e.g., 1–20 Gy total with <1–2 Gy daily dose) might 
convert the stroma by reducing transforming growth factor-beta 
(TGF-β) signaling and subsequently increasing the abscopal effect 
[13,14]. Low dose with high dose RT is currently underway in 
NCT02710253 at MD Anderson. Low-dose radiation has been used 
for decades (e.g., whole-lung RT 12–20 Gy for Ewing sarcoma) [15]. 
Some groups have suggested that irradiating parenchymal sites 
(e.g., the liver and lung) may be more associated with the abscopal 
effect because there are inherent differences in the microenviron-
ment of various organs [16]. 
In summary, a meaningful abscopal effect is an infrequent phe-
nomenon. Dose and fraction (conventional vs. hypofractionated vs. 
high-ablative dose), use of targeted image-guided techniques with 
a sharp fall-off of dosing (such as SABR), lymphocyte-sparing RT, 
tumor burden (oligometastases vs. polymetastases), targets (single 
site vs. multi-site), use of low-dose radiation, and irradiated sites 
(parenchymal vs. non-parenchymal) may affect the occurrence of 
abscopal effects. Furthermore, concomitant use of immunotherapy 
and the timing and sequence of RT in relation to immunotherapy 
can influence the abscopal effect and treatment outcomes. With 
emerging evidence of oligometastasis and the potential role of lo-
cal ablative therapy, clinicians should be aware of the potential role 
of RT in immunomodulation.  
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